Rabies Vaccine - PM Seed Stock

Inventor(s)

T. J. Wiktor, H. Koprowski, and S. Plotkin

Tech ID
WT6901
Background

The PM 1503 strain of rabies virus, developed at The Wistar Institute, has been successfully used worldwide to develop rabies vaccine for post-exposure treatment to prevent rabies infection of humans.


 The Wistar Institute has seed stock of the PM 1503 strain of rabies for use in production of vaccines. The Wistar seed stocks were grown on Vero cells, however, they can be adapted to grow on human diploid cells. This rabies vaccine seed stock has been licensed to select regional public health agencies and to for-profit companies who are developing vaccines for local distribution in selected countries, particularly China and India.

Key Words
PM rabies, rabies, Vaccine
Applications and Advantages

PM rabies seed stock may be used for development of human rabies vaccine.

Intellectual Property Status

The Wistar Institute can provide the proprietary biological material used to make the vaccine.

Licensing Opportunity

The PM 1503 strain of rabies virus is available for licensing to companies in China, India and other select countries for the purpose of making vaccine for local distribution.